|  |  |  | **Vaccine brand** | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **Moderna** | | **Pfizer** | |
|  |  |  | **Exposed** | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 2,072 | 2,072 | 890 | 890 |
| Age | - | Median [Q25 - Q75] | 34.00 [31.00 - 37.00] | 34.00 [31.00 - 37.00] | 33.00 [30.00 - 37.00] | 33.00 [30.00 - 37.00] |
| Age group | 12 to 24 | N (%) | 52 (2.5%) | 52 (2.5%) | 55 (6.2%) | 57 (6.4%) |
|  | 25 to 39 | N (%) | 1,779 (85.9%) | 1,780 (85.9%) | 747 (83.9%) | 749 (84.2%) |
|  | 40 to 55 | N (%) | 241 (11.6%) | 240 (11.6%) | 88 (9.9%) | 84 (9.4%) |
| Vaccine brand | Moderna | N (%) | 2,072 (100.0%) | 2,072 (100.0%) | - | - |
|  | Pfizer | N (%) | - | - | 890 (100.0%) | 890 (100.0%) |
| Trimester | Trimester 1 | N (%) | 654 (31.6%) | 642 (31.0%) | 228 (25.6%) | 228 (25.6%) |
|  | Trimester 2 | N (%) | 893 (43.1%) | 905 (43.7%) | 368 (41.3%) | 371 (41.7%) |
|  | Trimester 3 | N (%) | 525 (25.3%) | 525 (25.3%) | 294 (33.0%) | 291 (32.7%) |
| Number visits prior year | - | Median [Q25 - Q75] | 19.00 [10.00 - 34.00] | 34.00 [17.50 - 56.00] | 19.00 [10.00 - 32.00] | 34.00 [18.00 - 54.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 401 (19.4%) | 364 (17.6%) | 195 (21.9%) | 189 (21.2%) |
|  | Heart conditions | N (%) | 54 (2.6%) | 50 (2.4%) | 27 (3.0%) | 21 (2.4%) |
|  | Eclampsia preeclampsia | N (%) | 21 (1.0%) | 27 (1.3%) | 8 (0.9%) | 10 (1.1%) |
|  | Asthma | N (%) | 120 (5.8%) | 136 (6.6%) | 56 (6.3%) | 65 (7.3%) |
|  | Pneumonia | N (%) | 53 (2.6%) | 52 (2.5%) | 27 (3.0%) | 23 (2.6%) |
|  | Hypothyroidism | N (%) | 204 (9.8%) | 211 (10.2%) | 74 (8.3%) | 95 (10.7%) |
|  | Depressive disorder | N (%) | 103 (5.0%) | 116 (5.6%) | 37 (4.2%) | 42 (4.7%) |
|  | Gestational diabetes | N (%) | 90 (4.3%) | 91 (4.4%) | 54 (6.1%) | 46 (5.2%) |
|  | Chronic hypertension | N (%) | 46 (2.2%) | 55 (2.7%) | 17 (1.9%) | 19 (2.1%) |
|  | Anxiety disorder | N (%) | 586 (28.3%) | 547 (26.4%) | 224 (25.2%) | 216 (24.3%) |
|  | Chronic obstructive lung disease | N (%) | <5 (<5%) | 5 (0.2%) | 0 (0.0%) | <5 (<5%) |
| Drugs prior 180 days | Propulsives | N (%) | 69 (3.3%) | 43 (2.1%) | 32 (3.6%) | 27 (3.0%) |
|  | Progestogens | N (%) | 130 (6.3%) | 126 (6.1%) | 62 (7.0%) | 46 (5.2%) |
|  | Antimycotics systemic | N (%) | 9 (0.4%) | 7 (0.3%) | <5 (<5%) | 5 (0.6%) |
|  | Estrogens | N (%) | 112 (5.4%) | 117 (5.6%) | 46 (5.2%) | 48 (5.4%) |
|  | Antithrombotics | N (%) | 187 (9.0%) | 125 (6.0%) | 80 (9.0%) | 60 (6.7%) |
|  | Antihistamines systemic | N (%) | 329 (15.9%) | 303 (14.6%) | 121 (13.6%) | 184 (20.7%) |
|  | Antidepressants | N (%) | 96 (4.6%) | 105 (5.1%) | 34 (3.8%) | 39 (4.4%) |
|  | Immunoglobulins | N (%) | 83 (4.0%) | 82 (4.0%) | 39 (4.4%) | 28 (3.1%) |
|  | Analgesics and antipyretics | N (%) | 692 (33.4%) | 616 (29.7%) | 364 (40.9%) | 346 (38.9%) |
|  | Antiinflammatory antirehumatic | N (%) | 330 (15.9%) | 315 (15.2%) | 168 (18.9%) | 166 (18.7%) |
|  | Antiepileptics | N (%) | 27 (1.3%) | 28 (1.4%) | 13 (1.5%) | 15 (1.7%) |
|  | Antibacterials systemic | N (%) | 449 (21.7%) | 393 (19.0%) | 214 (24.0%) | 194 (21.8%) |